Pre-Test Management and Challenges of Cervical Cancer Treatment in the Second Line and Beyond Pre-Test The median time to response and median duration of response observed in the innovaTV 204 trial evaluating tisotumab in patients with previously treated recurrent and/or metastatic cervical cancer are ______ and ______, respectively. 1.4 months and 8.3 months 2.4 months and 9.3 months 3.4 months and 10.3 months 4.4 months and 11.3 months Unsure Which of the following used in combination with pembrolizumab as second/third-line treatment in the setting of recurrent or metastatic cervical cancer in the ENGOT-cx8/GOG-3024/innovaTV 205 trial has shown durable antitumor activity? Balstilimab Cemiplimab Nivolumab Tisotumab Unsure Ocular adverse reactions occurred in ______ of patients with cervical cancer treated with tisotumab across clinical trials? 20% 40% 60% 80% Unsure How confident are you in your ability to develop patient-centered strategies utilizing evidence-based, real-world safety and efficacy data to optimize treatment outcomes in patients with recurrent or metastatic PD-L1-negative cervical cancer? Very confident Confident Somewhat confident Not very confident Not at all confident
